A Phase 2b, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and Without Type 2 Diabetes
A Phase 2b, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and Without Type 2 Diabetes
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will last about 64 weeks.
Inclusion Criteria:
Exclusion Criteria:
In addition to exclusion criteria in Master Protocol CWMM (NCT06143956):
LillyTrials@Lilly.com317-615-4559
clinical_inquiry_hub@lilly.com
Chandler, Arizona 85225, United States
Tucson, Arizona 85712, United States
Huntington Park, California 90255, United States
Troy, Michigan 48098, United States